Tag Archives: GHP

Global Health Progress Releases Non-Communicable Diseases Partnerships and Programs List

Global Health Progress compiled a list of non-communicable disease treatment programs from around the world, highlighting partnerships to address cancer treatment, diabetes care, epilepsy programs and more. The programs, sponsored by leading companies like Astra Zeneca, Abbott, Novo Nordisk, and Bayer Healthcare, aim to increase awareness of non-communicable diseases in the developing world.

“Our goal in creating this list is to bring awareness to these companies who work so hard at fighting diseases in developing countries,” explains Mark Grayson, Vice President of Communications and Public Affairs at PhRMA and key developer in the Global Health Progress initiative. “Non-communicable diseases are the leading killer in many of these countries, and without the help of these programs they would continue to increase.”

Global Health Progress works with partner groups to encourage and sustain funding for the research and development of healthcare in developing nations. Improving health care systems and access to medicines, especially in the developing world, requires multifaceted approaches and solutions. Research-based biopharmaceutical companies are active partners in some of the largest and boldest health initiatives that explore new and effective ways to provide treatment, care and education to millions of people in developing countries.

Read the full list of non-communicable disease treatment programs here:
http://globalhealthprogress.org/mediacenter/wp-content/uploads/NCD-Health-Partnerships-and-Programs_Worldwide-05-02-11.pdf.

Via EPR Network
More Healthcare press releases

Medical Innovation Protection Stressed in EU-India Free Trade Agreement Talks

The Financial Express published an article on the Free Trade Agreement (FTA) talks that continue between the European Union (EU) and India. One of the most discussed and disagreed upon parts of the proposed FTA involves the need for protecting the intellectual property of pharmaceutical companies in order to promote medical innovation and investment in the development of new medicines and research. This disagreement about whether data exclusivity in the pharmaceutical sector should be included has resulted in the delay of finalizing the FTA.

Pharmaceutical companies rely on data exclusivity to protect the investment made in developing the medication that is used throughout the world. Millions of dollars are spent on clinical trials to prove the safety and effectiveness of these drugs. These exclusive rights prevent competitors from obtaining marketing licenses for lower cost versions of these drugs.

Global Health Progress (GHP) is committed to being part of the effort to create a sustainable health care system that includes improving access to health care and continuing medical innovation and progress for all people. While the pharma industry is divided on the issue, GHP supports efforts to improve regulations protecting pharmaceutical companies’ intellectual property. Without this protection, the funding of studies that bring these medications to market could suffer.

Improving health care systems and access to medicines, especially in the developing world, requires multifaceted approaches and solutions. Research-based biopharmaceutical companies are active partners in some of the largest and boldest health initiatives that explore new and effective ways to provide treatment, care and education to millions of people in developing countries.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector.

www.globalhealthprogress.org;

twitter.com/globalhealth;

facebook.com/pages/Global-Health-Progress/124850684219049;

linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases

Global Health Progress Amplifies Report Calling for Funding Products to Fight Neglected Tropical Diseases

The third-annual Global Funding of Innovation for Neglected Diseases (G-FINDER) survey was released last week revealing both good and bad news for the funding of neglected diseases in the developing world. In a press release issued by Policy Cures, an independent group providing research and analysis for those involved in the creation of new pharmaceuticals for neglected diseases, the group reveals that while funding for neglected diseases has increased, funding for new products has decreased.

Funders appear to be focusing more of their money toward traditional basic research. This shift has caused a $50 million drop in funding for Product Development Partnerships (PDP), non-profit organizations that partner with external organizations to drive product development for neglected diseases, including neglected tropical diseases.

Report author Dr Mary Moran, Director of Policy Cures warns funders not to “take their eyes off the ball” in the press release, stating that while the increase in funding is encouraging it is important that the funds are spent wisely.

Global Health Progress has worked with partner groups to encourage and sustain funding for the research and development of new products. The innovative research and development (R&D) of new drugs and vaccines is a critical component of improving health care and combating epidemics of neglected tropical diseases in developing countries. There are no vaccines or cures for some widespread and life threatening diseases such as malaria, while existing treatments for diseases such as tuberculosis are becoming less effective due to drug resistance.

Read the full press release from Policy Cures here:
http://globalhealthprogress.org/mediacenter/wp-content/uploads/G-FINDER_Year_3_media_release.pdf,
or read the G-FINDER report on the Policy Cures website:
http://www.policycures.org/downloads/g-finder_2010.pdf.

Via EPR Network
More Healthcare press releases

New UN Program Will Ensure Developing Nations Continue to Have Access to Drugs Effective At Treating Malaria

Earlier this week, the United Nations announced a new plan of action designed to help fight disease resistance to artemisinin, the world’s most potent treatment for malaria. Launched by the UN World Health Organization (WHO) and the Roll Back Malaria Partnership (RBM), the groups hope to better contain and prevent resistance to artemisinins, the critical component of artemisinin-based combination therapies (ACTs), which are currently the most effective weapon in treating falciparum malaria.

The WHO’s announcement describes the plan as a five-step process which “aims to contain and prevent artemisinin resistance by stopping the spread of resistant parasites, increase monitoring and surveillance for artemisinin resistance, improve access to malaria diagnostic testing and rational treatment with ACTs, invest in artemisinin resistance-related research, and motivate action and mobilize resources.”

Global Health Progress is hopeful that this action plan will help to ensure that developing nations continue to have access to drugs that most effectively treat malaria. Many malaria-stricken countries lack the resources needed to keep an effective health care system running smoothly. Strong, effective health systems are vital to helping those in need of access to drugs, and health care improvements made today will strengthen the ability of countries to develop sustainable systems that can meet tomorrow’s challenges. Stopping the spread of drug-resistant strains of malaria and other diseases are essential to these goals.

Investing in local R&D capacity and national research systems is another way research-based biopharmaceutical companies help strengthen health systems. Local production can play a valuable role in building overall local capacity and enabling developing countries to increase access to essential medicines.

It is the responsibility of the entire international community to facilitate access to medicines. Success depends on all sectors working in partnership; not only to make medicines more accessible, but also to ensure continued innovation into new medicines for the treatment and prevention of all diseases.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector. www.globalhealthprogress.org;  twitter.com/globalhealth; facebook.com/pages/Global-Health-Progress/124850684219049;  linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases